- Home
- OTLK vs HUIZ Comparison
OTLK vs HUIZ Comparison
Compare OTLK & HUIZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OTLK | HUIZ |
|---|---|---|
| Founded | 2010 | 2006 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Specialty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.7M | 31.5M |
| IPO Year | 2016 | 2020 |
Fundamental Metrics
Financial Performance| Metric | OTLK | HUIZ |
|---|---|---|
| Price | $0.51 | $2.25 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $3.83 | $2.30 |
| AVG Volume (30 Days) | ★ 12.7M | 32.3K |
| Earning Date | 02-13-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.25 |
| Revenue | $1,413,535.00 | ★ $186,519,166.00 |
| Revenue This Year | $1,578.49 | $22.67 |
| Revenue Next Year | $153.58 | $8.55 |
| P/E Ratio | ★ N/A | $9.08 |
| Revenue Growth | N/A | ★ 19.12 |
| 52 Week Low | $0.50 | $1.50 |
| 52 Week High | $3.39 | $4.53 |
Technical Indicators
Market Signals| Indicator | OTLK | HUIZ |
|---|---|---|
| Relative Strength Index (RSI) | 25.51 | 31.38 |
| Support Level | $0.51 | $2.20 |
| Resistance Level | $0.54 | $2.39 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 16.19 | 25.00 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About HUIZ Huize Holding Limited
Huize Holding Ltd is an independent online insurance product and service platform in China. The company distributes on its platform insurance products underwritten by the insurance companies that cooperate with the company, which the company refers to as its insurer partners, and helps them reach a large number of insurance clients. The company's platform offers a digitalized insurance purchase experience and services through various internet and mobile internet channels. The company generates revenues from the insurance brokerage fees paid by its insurer partners.